Loading…
Develops therapies for autoimmune kidney diseases, led by atacicept for IgA nephropathy.
Develops therapies for autoimmune kidney diseases, led by atacicept for IgA nephropathy.
Has no approved product and earns no sales; spending on late-stage trials and launch preparation is funded by money raised from investors. Its lead drug, atacicept, was licensed from Merck KGaA, which would be owed milestone and royalty payments if it reaches the market.
Moat: none (IP / patents). Differentiated dual-pathway BAFF/APRIL mechanism but a competitive, fast-evolving IgA nephropathy field.
Headquarters: Brisbane, California, US · Founded: 2016 · Employees: 249
Size Vera Therapeutics (VERA) is a United States Health Care company (Biotechnology) with a market value of $2.15B, the 1751st largest of 3,117 United States companies the cockpit tracks. Shares closed at $29.79 on 6 Nov 2026.
Performance Over six months the shares fell 17.7%, against +15.5% for the median peer and -1.1% for the United States market (cap-weighted) — 3rd lowest of 21 in its peer set.
Short interest Short interest is 18.9% of the free float (15 Oct 2026).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$1.21M | -$468,000 | -$2.17M | $1.86M | $846,000 |
| EBITDA | -$415M | -$315M | -$165M | -$104M | -$91.7M |
| Net income | -$402M | -$300M | -$152M | -$96.0M | -$89.1M |
| Free cash flow | -$339M | -$242M | -$136M | -$92.2M | -$67.7M |
| Capital expenditure | $522,000 | $630,000 | $972,000 | $63,000 | $62,000 |
| Total debt | $75.2M | $77.3M | $54.6M | $53.7M | $31.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Vera Therapeutics VERA | $2.15B | -18% | n/a | n/a | n/a | n/a |
| Novartis NOVN.SW | $298B | +15% | -4% | 30% | 6.3× | 1.7% |
| Travere Therapeutics TVTX | $4.76B | +16% | +49% | -3% | 7.5× | 16.7% |
| Caltagirone CALT.MI | $1.26B | +1% | +10% | 10% | 1.1× | 0.9% |
| Otsuka Hldgs 4578.T | $38.6B | +2% | +11% | 18% | 2.2× | 0.4% |
| Vertex Pharmaceuticals VRTX | $139B | +27% | +11% | 35% | 10.7× | 6.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | VERA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.2% | +1.7% | 9th lowest of 21 |
| 6-month return | -17.7% | +15.5% | 3rd lowest of 21 |
| Distance from 52-week high | -46.9% | -25.4% | 2nd lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Vera Therapeutics VERA | United States | $2.15B | -18% | n/a | n/a | n/a | n/a | n/a |
| Hitgen 688222.SS | China | $2.12B | +23% | +42% | 27% | 19.1× | 38.7% | +16.8% |
| Shenzhen Kangtai Biological Products 300601.SZ | China | $2.11B | -9% | -9% | 6% | 5.6× | 25.3% | +3.4% |
| Lakefront Biotherapeutics LKFT.AS | Netherlands | $2.19B | +25% | +259% | 60% | n/a | n/a | n/a |
| Recursion Pharmaceuticals RXRX | United States | $2.19B | +6% | +56% | -725% | 25.1× | n/a | n/a |
| Aurinia Pharmaceuticals AUPH | United States | $2.21B | +8% | +21% | 45% | 5.5× | 5.1% | +41.4% |
| Immunome IMNM | United States | $2.21B | -17% | -100% | n/a | n/a | n/a | n/a |
| SKBS 302440.KS | South Korea | $2.22B | -11% | +23% | -25% | 4.5× | n/a | n/a |
| Vir Biotechnology VIR | United States | $2.07B | +34% | +1,496% | -92% | 5.4× | n/a | n/a |
| Replimune REPL | United States | $2.05B | +547% | n/a | n/a | n/a | n/a | n/a |
| Sinocelltech 688520.SS | China | $2.25B | -23% | -40% | -75% | 15.6× | n/a | n/a |
| Trevi Therapeutics TRVI | United States | $2.04B | -1% | n/a | n/a | n/a | n/a | n/a |
| Vimian VIMIAN.ST | Sweden | $2.26B | +41% | +8% | 19% | 4.9× | 12.5% | +44.5% |
| Septerna SEPN | United States | $2.28B | +105% | +13,520% | -57% | 19.5× | 18.7% | n/a |
| First Tracks Biotherapeutics TRAX | United States | $2.01B | +145% | n/a | n/a | n/a | n/a | n/a |
| Hemab Therapeutics COAG | United States | $2.29B | +95% | n/a | n/a | n/a | n/a | n/a |
| GemPharmatech 688046.SS | China | $2.01B | +59% | +25% | 22% | 13.3× | 35.7% | +24.8% |
| Zealand Pharma A/S ZEAL.CO | Denmark | $2.32B | -32% | -49% | 51% | 0.3× | n/a | n/a |
| BioCryst Pharmaceuticals BCRX | United States | $1.97B | -11% | +60% | 42% | 2.5× | -10.6% | +117.9% |
| Celldex Therapeutics CLDX | United States | $2.35B | -12% | -97% | -206,220% | 10,375.3× | n/a | n/a |
| Maravai Lifesciences MRVI | United States | $1.95B | +108% | -3% | -13% | 9.3× | n/a | n/a |